Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock
Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicine, today announced that it has entered into a securities ...
Insider Monkey4d
10 Hot Biotech Stocks Under $5
Its main drug, onvansertib, is an oral Polo-like Kinase 1 (PLK1) inhibitor targeting KRAS-mutated colorectal cancer (mCRC) and other tumors. The company has shown promising clinical results and ...
Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates
Event to be held via webcast on March 25, 2025 at 4:00 p.m. ETTo highlight differentiated drug discovery capabilities with its Generative ...
Morningstar6d
Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates
but also of PLK1 to drive pro-apoptotic cell death, as demonstrated in preclinical studies against benchmark inhibitors. In addition, the company has a preclinical cell cycle program with an ...